Atrial natriuretic peptide
- Generic Name
- Atrial natriuretic peptide
- Drug Type
- Biotech
- CAS Number
- 85637-73-6
E-Star BioTech Initiates Phase 2 Trial of MANP for Resistant Hypertension Treatment
• E-Star BioTech has dosed the first patient in its BOLD-HTN Phase 2 clinical trial, evaluating MANP for resistant hypertension treatment, marking a significant milestone in cardiovascular medicine.
• The company's MANP therapy, licensed from Mayo Clinic, has shown promising safety profiles in multiple Phase 1 studies involving patients with hypertension and cardiometabolic syndrome.
• With global hypertension affecting 1.28 billion adults and only 21% achieving proper control, this trial addresses a critical unmet medical need in cardiovascular health management.
Low-Dose Dobutamine Investigated for Acute Myocardial Infarction
• A clinical trial is underway to assess the efficacy of low-dose dobutamine in patients with acute myocardial infarction (AMI) at intermediate to high risk.
• The trial aims to determine if a 24-hour infusion of dobutamine can improve hemodynamic function and reduce peak proBNP levels compared to placebo.
• The study employs a weight-standardized dobutamine infusion of 5 μg/kg/min, with potential reduction to 2.5 μg/kg/min in case of tachyarrhythmia.
• The primary endpoint is the difference in peak proBNP levels within 48 hours, with secondary endpoints including hemodynamic function and biomarker changes.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath